N
Nicola J. Kalk
Researcher at King's College London
Publications - 59
Citations - 1591
Nicola J. Kalk is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Alcohol dependence. The author has an hindex of 18, co-authored 50 publications receiving 1118 citations. Previous affiliations of Nicola J. Kalk include Charing Cross Hospital & University of Bristol.
Papers
More filters
Journal ArticleDOI
Prevalence of problematic smartphone usage and associated mental health outcomes amongst children and young people: a systematic review, meta-analysis and GRADE of the evidence.
Samantha Sohn,Phillipa Rees,Bethany Wildridge,Nicola J. Kalk,Nicola J. Kalk,Benjamin Richard Carter,Benjamin Richard Carter +6 more
TL;DR: PSP is an evolving public health concern that requires greater study to determine the boundary between helpful and harmful technology use and policy guidance is needed to outline harm reduction strategies.
Journal ArticleDOI
Investigation into the neural correlates of emotional augmentation of clinical pain
Petra Schweinhardt,Petra Schweinhardt,Nicola J. Kalk,Karolina Wartolowska,Iain P. Chessell,P Wordsworth,Irene Tracey +6 more
TL;DR: Results suggest that the MPFC may play an important role in mediating the relationship between depressive symptoms and clinical pain severity in RA, possibly by engaging brain areas important for affective and self-relevant processing.
Journal ArticleDOI
Neuroinflammation in treated HIV-positive individuals A TSPO PET study
Jaime H. Vera,Qi Guo,James H. Cole,Adriano Boasso,Louise Greathead,Peter Kelleher,Eugenii A. Rabiner,Nicola J. Kalk,Courtney A. Bishop,Roger N. Gunn,Paul M. Matthews,Alan Winston +11 more
TL;DR: Cognitively healthy HIV-positive individuals show evidence for a chronically activated brain innate immune response and elevated blood markers of microbial translocation despite effective control of plasma viremia, suggesting a possible role in cognitive impairments found in some HIV- positive patients despite effective treatment.
Journal ArticleDOI
Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study:
David R. Owen,Qi Guo,Qi Guo,Nicola J. Kalk,Alessandro Colasanti,Dimitra Kalogiannopoulou,Rahul Dimber,Yvonne Lewis,Vincenzo Libri,Julien Barletta,Joaquim Ramada-Magalhaes,Aruloly Kamalakaran,David J. Nutt,Jan Passchier,Paul M. Matthews,Paul M. Matthews,Roger N. Gunn,Eugenii A. Rabiner +17 more
TL;DR: In this article, the authors used PBR28 with the TSPO ligand XBD173 to determine the non-displaceable volume of distribution (VND) and hence estimate the binding potential (BPND).
Journal ArticleDOI
The clinical pharmacology of acamprosate
TL;DR: Although acamprosate has been called an anticraving drug, its subjective effects are subtle and relate to diminished arousal, anxiety and insomnia, which parallel preclinical findings of decreased withdrawal symptoms in animals treated with acamposate.